Logo

Ciphergen Stockholders Approve SELDI Divestiture to Bio-Rad

Oct 29, 2006
NEW YORK (GenomeWeb News) — Ciphergen Biosystems’ shareholders have given the company the green light to sell its proteomics instrument business to Bio-Rad Laboratories.
 
Under the terms of the agreement, originally disclosed in August, Ciphergen will unload the hardware branch to Bio-Rad for about $20 million in cash and a $3 million equity investment.
 
Ciphergen, which will now focus on its specialty diagnostic business, said it expects the deal to close before Nov. 1.
 
With the acquisition, Bio-Rad will be able to make and market Ciphergen’s surface enhanced laser desorption ionization technology, also known as SELDI, to the life sciences market for various proteomics applications.
 
Bio-Rad recently made two other purchases into the medical diagnostics market: The company bought Blackhawk Biosystems, a maker of infectious disease diagnostic products, for an undisclosed sum, and acquired Provalis’ medical diagnostic business for $3 million.
 
 

Filed under

Proteomics & Protein Research
proteomics
Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.